Chemed (CHE) Rating Lowered to Hold at ValuEngine

Chemed (NYSE:CHE) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Friday.

CHE has been the topic of several other reports. KeyCorp restated a “hold” rating on shares of Chemed in a report on Friday, October 27th. Royal Bank Of Canada restated a “hold” rating and set a $209.00 price target on shares of Chemed in a report on Tuesday, October 3rd. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Finally, Oppenheimer boosted their price target on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Chemed currently has an average rating of “Hold” and a consensus price target of $236.00.

Chemed (NYSE:CHE) traded up $1.61 during trading on Friday, reaching $247.53. The company’s stock had a trading volume of 135,158 shares, compared to its average volume of 107,057. Chemed has a 1 year low of $148.84 and a 1 year high of $248.31. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The company has a market capitalization of $3,950.00, a PE ratio of 30.48, a PEG ratio of 5.23 and a beta of 1.16.

Chemed (NYSE:CHE) last released its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.73 earnings per share. research analysts forecast that Chemed will post 4.73 earnings per share for the current year.

In related news, insider David Patrick Williams sold 11,000 shares of Chemed stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total value of $2,654,080.00. Following the transaction, the insider now directly owns 74,857 shares of the company’s stock, valued at $18,061,496.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Naomi C. Dallob sold 750 shares of Chemed stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total value of $166,567.50. Following the completion of the transaction, the vice president now directly owns 9,097 shares in the company, valued at $2,020,352.73. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 45,179 shares of company stock worth $10,479,699. 4.90% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the stock. Kalos Management Inc. lifted its stake in shares of Chemed by 0.7% in the second quarter. Kalos Management Inc. now owns 6,521 shares of the company’s stock worth $1,333,000 after acquiring an additional 45 shares during the period. Capstone Asset Management Co. lifted its stake in shares of Chemed by 2.7% in the second quarter. Capstone Asset Management Co. now owns 1,857 shares of the company’s stock worth $380,000 after acquiring an additional 49 shares during the period. Amalgamated Bank lifted its stake in shares of Chemed by 2.9% in the second quarter. Amalgamated Bank now owns 2,203 shares of the company’s stock worth $451,000 after acquiring an additional 62 shares during the period. State Board of Administration of Florida Retirement System lifted its stake in Chemed by 0.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 8,681 shares of the company’s stock valued at $1,776,000 after buying an additional 64 shares during the period. Finally, Bbva Compass Bancshares Inc. lifted its stake in Chemed by 2.1% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,822 shares of the company’s stock valued at $782,000 after buying an additional 77 shares during the period. 97.72% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Chemed (CHE) Rating Lowered to Hold at ValuEngine” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/03/chemed-che-rating-lowered-to-hold-at-valuengine.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply